HOME STORY OF OUR FIRM SEARCH
ASBESTOS DRUGS POLLUTANTS ACCIDENTS MALPRACTICE
English En Français

FREE LEGAL REVIEW

First Name
Last Name
Home Phone
Work Phone
City and State
Email
Were you diagnosed with Asbestosis? Yes
Were you diagnosed with lung cancer? Yes
Were you diagnosed with Mesothelioma? yes
What is your date of diagnosis?
Additional Comments
Best time to call?

Mesothelioma Publication - Calretinin Antibodies

This is an abstract of an article about mesothelioma and calretinin antibodies first published at PubMed by the NIH.

Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma.

Granville LA, Younes M, Churg A, Roggli VL, Henderson DW, Cagle PT.
U.T. MD Anderson Cancer Center, Houston, TX, USA. LAGranvi@mdanderson.org
Appl Immunohistochem Mol Morphol. 2005 Mar;13(1):75-9.

Of putative specific markers for diffuse malignant mesothelioma, nuclear staining with Zymed polyclonal calretinin antibody has shown the best specificity to date for epithelial diffuse malignant mesothelioma versus adenocarcinoma. We compared specificity and sensitivity of this polyclonal antibody for diagnosis of diffuse malignant mesothelioma with a new monoclonal antibody from DAKO. One hundred eighteen adenocarcinomas and 111 diffuse malignant mesotheliomas-70 epithelial, 22 sarcomatous, and 19 biphasic-were immunostained with calretinin antibodies from Zymed (polyclonal rabbit, prediluted, PAD:DC8) and DAKO(monoclonal mouse, 1:100, clone DAK Calret 1) using manufacturer-recommended procedures.

Cases were blinded and assessed for nuclear versus cytoplasmic staining, percent positive cells, and background.

Both antibodies showed similar positive predictive values for diffuse malignant mesothelioma by nuclear staining (Zymed=95%; DAKO=97%). False positives in 4 (3.4%) and 2 (1.7%) adenocarcinomas, respectively, stained greater than 10% of cells. Sensitivity for epithelial malignant mesothelioma was slightly less for DAKO antibody (Zymed=80%; DAKO=73%). Neither antibody performed well on sarcomatous malignant mesothelioma (Zymed=2/22; DAKO=1/22). Both antibodies are useful in the diagnosis of epithelial malignant mesothelioma, although monoclonal antibody is slightly less sensitive.

Exposure to asbestos is known to cause serious illnesses such as mesothelioma, asbestos-related lung cancer or asbestosis.

If you or a loved one has been diagnosed with an asbestos illness, contact our lawyers today for a free review of your case. A Weitz & Luxenberg representative will contact you as soon as possible.

Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos
Real Stories


IN THIS SECTION
Farnesyltransferase Inhibitors
Cancer Immunotherapy
Great Britain
Poland
Pemetrexed Therapy
Sv40 Specific Recall Immunity
Polish Cases
Extra Pleural Pneumonectomy
Intraoperative Radiation Therapy
Calretinin
Hyaluronan
Granulocyte Colony Stimulating Factor
Mesothelioma in Canada
Pemetrexed (Alimta)
Calretinin Antibodies
Greece
Neoplasia
FDA Pemetrexed
Secreted Frizzled Related Protein
Tumor Necrosis
Podoplanin
Lymphohistiocytoid
Mesothelioma Pathogenesis
Diagnostic Difficulties
Mesothelioma from Adenocarcinoma
Mesothelial Proliferation
ThinPrep Cytospin
Effusion
Chemotherapy Options
Heparanase
Malignant Deciduoid
Mortality
Pemetrexed in Malignant Pleural Mesothelioma
Pleural Mesothelioma
Prognostic Analysis
Italian Mortality Rates
Vinorelbine and Oxaliplatin
DNA Methylation Profiles
Primary Malignant Pericardial Mesothelioma
Abdominal CAT Scans
China
Disseminated Malignant
Statistical Validation
Pathogenesis
Lung Adenocarcinoma
Japan


RETURN BACK TO
Mesothelioma
Mesothelioma Resource Center
Mesothelioma
Information about Diagnosis
Latest News

Mesothelioma Lawyer

Asbestos Lawyer

Mesothelioma Attorney

Asbestos Attorney

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

see also:

Mesothelioma Pathogenesis Pathogenesis Malignant Pleural Mesothelioma | Weitz and Luxenberg
Information about the pathogenesis of malignant pleural mesothelioma

Pemetrexed (Alimta) Second-line treatment against mesothelioma using Pemetrexed (Alimta)
News about a mesothelioma treatment using Pemetrexed (Alimta)

National Mesothelioma Publications The National Institute of Health mesothelioma research publications
Mesothelioma publications from the National Institute of Health